Skip to main content
. 2022 Jul 4;31(23):3987–4005. doi: 10.1093/hmg/ddac083

Figure 1.

Figure 1

Insoluble CHCHD2 is increased and correlates with insoluble α-synuclein levels in the brains of LBD patients. (A) Sarkosyl soluble and insoluble representative immunoblots for CHCHD2, α-synuclein and S129 phospho-α-synuclein from the frontal cortex of control subjects and LBD patients. (B) Quantitative analysis of sarkosyl soluble and (C) insoluble CHCHD2 levels. Error bars represent mean ± SEM; n = 6 control, n = 17 LBD patients; t-test; *P < 0.05. (D) Correlation of insoluble CHCHD2 and α-synuclein levels. n = 6 control, n = 17 LBD patients.